scholarly article | Q13442814 |
P356 | DOI | 10.1212/01.WNL.0000041913.97883.8B |
P698 | PubMed publication ID | 12473787 |
P2093 | author name string | David A Pearce | |
Subrata Chattopadhyay | |||
David A Wenger | |||
Elizabeth Kriscenski-Perry | |||
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | autoantibody | Q785022 |
P304 | page(s) | 1816-1817 | |
P577 | publication date | 2002-12-01 | |
P1433 | published in | Neurology | Q1161692 |
P1476 | title | An autoantibody to GAD65 in sera of patients with juvenile neuronal ceroid lipofuscinoses. | |
P478 | volume | 59 |
Q36986268 | Antigen presenting cell abnormalities in the Cln3(-/-) mouse model of juvenile neuronal ceroid lipofuscinosis |
Q50056608 | Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. |
Q90400660 | Combined Anti-inflammatory and Neuroprotective Treatments Have the Potential to Impact Disease Phenotypes in Cln3 -/- Mice |
Q48421299 | Distinct patterns of serum immunoreactivity as evidence for multiple brain-directed autoantibodies in juvenile neuronal ceroid lipofuscinosis |
Q34719788 | High definition profiling of autoantibodies to glutamic acid decarboxylases GAD65/GAD67 in stiff-person syndrome |
Q33814536 | High levels of Anti-GAD65 and Anti-Ro52 autoantibodies in a patient with major depressive disorder showing psychomotor disturbance |
Q34142898 | Immunosuppression alters disease severity in juvenile Batten disease mice |
Q46578546 | Proteolytic degradation of glutamate decarboxylase mediates disinhibition of hippocampal CA3 pyramidal cells in cathepsin D-deficient mice. |
Q35681068 | Selectivity and types of cell death in the neuronal ceroid lipofuscinoses |
Q64044847 | Short-Term Administration of Mycophenolate Is Well-Tolerated in CLN3 Disease (Juvenile Neuronal Ceroid Lipofuscinosis) |
Q64040442 | Therapeutic landscape for Batten disease: current treatments and future prospects |
Q37260497 | Vision loss in juvenile neuronal ceroid lipofuscinosis (CLN3 disease) |
Search more.